Aintree – Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn’s Disease

 Authors: Catt H, Bodger K, Kirkham JJ, Hughes DA.

Source: Pharmacoeconomics. 2019 Aug 2.

doi: 10.1007/s40273-019-00826-0. [Epub ahead of print]

PMID: 31372948 [PubMed – as supplied by publisher]

Leave a Reply

Your email address will not be published. Required fields are marked *